DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
CT-011 is an investigational drug.
There have been 12 clinical trials for CT-011. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2007.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Neoplasms, Plasma Cell, and Multiple Myeloma. The leading clinical trial sponsors are CureTech Ltd, Augusta University, and Teva Pharmaceutical Industries.
Recent Clinical Trials for CT-011
|Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma||CureTech Ltd||Phase 1/Phase 2|
|Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma||Yvonne Efebera||Phase 1/Phase 2|
|Gemcitabine and CT-011 for Resected Pancreatic Cancer||Augusta University||Phase 2|